Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions

The GHIT Fund will invest approximately JPY 444 million (USD 2.9 million¹) in two malaria projects: the development of malaria chemoprevention drug through a partnership among Shionogi & Co., Ltd., Nagasaki University, National Institute of Infectious Diseases, and Medicines for Malaria Venture (MMV), and therapeutic drug development led by Eisai Co., Ltd., the Scripps Research Institute, and International Centre for Genetic Engineering and Biotechnology (ICGEB).

For NTDs, the GHIT Fund will also invest approximately JPY 1.2 billion (USD 7.9 million¹) in two projects: drug development for onchocerciasis and lymphatic filariasis led by Eisai Co., Ltd., University Hospital Bonn, and Helmholtz Centre for Infection Research, and the development of a treatment for Chagas disease led by Mitsubishi Tanabe Pharma Corporation and Drugs for Neglected Diseases initiative (DNDi).

The GHIT Fund plays a catalytic role in matching Japanese and global partners to accelerate R&D resulting in the support of over 180 development partners since 2013. Through global partnerships, the GHIT Fund aims to promote open innovation in R&D and create an environment that enables the rapid delivery of products to patients in need.

Please refer to Appendix 1 for a detailed description of each project and its development stage.

As of March 31, 2024, the GHIT Fund invested in 36 projects, including 12 discovery projects, 16 preclinical projects, and 8 clinical trials³ in the portfolio. The total amount of investments since 2013 is JPY 33.2 billion (USD 219 million) (Appendix 2).

¹USD1 = JPY151.33, the approximate exchange rate on March 31, 2024.
² These awarded projects were selected and approved as new investments from among proposals to RFP2023-001 for the Product Development Platform, which was open for applications from November 2022 to July 2023.
³ This number includes projects in the registration phase.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical disease     s.
https://www.ghitfund.org/en

Appendix 1. Project Details    

G2023-218

3. National Institute of Infectious Diseases (Japan)

4. Medicines for Malaria Venture (MMV) (Switzerland)

[Project design]
The project aims to provide a preclinical candidate in two years. A frontrunner compound will be evaluated for the in vivo safety and DMPK studies. In parallel, a lead optimization study will be conducted in search for the second runner candidate with even greater promise than the frontrunner candidate. The most promising compounds will be subjected to extensive in vivo safety and pharmacokinetics studies to satisfy MMV's preclinical candidate criteria.

G2023-108

3. International Centre for Genetic Engineering and Biotechnology (ICGEB) (India)

[Project design]

Promising, recently generated novel antimalarial compounds will be synthesized and profiled in in vivo efficacy studies, exploratory safety studies and multi-species pharmacokinetic studies with the goal of selecting a preclinical development candidate.

G2023-211

3. Helmholtz Centre for Infection Research (HZI) (Germany)

[Project design]

To achieve this goal, we will conduct the following studies to improve our knowledge of CorA and produce GMP drug substance that will be used in the phase 1 trial. Because CorA is a predicted substrate of enzymes that detoxify substances in the body, we will determine the metabolism of CorA by the enzymes that are predicted to metabolize CorA. Prior to applying for a phase 1 trial authorization, new drugs must be shown to be nontoxic. Therefore, we will conduct a GLP toxicity study, including measuring plasma levels of CorA. With the latter data, we will refine our PK/PD model that will allow us to determine the best human dose and regimen for the phase 1 trial. Our research and innovation packages will provide us with a better understanding of the chemical nature of CorA (e.g., can it be crystalized or co-crystallized?) that may be used to improve the production or stability of CorA. With the GHIT funding we will also produce CorA material for the phase 1 study, including highly pure standards needed for bioanalysis of plasma samples in the phase 1 study.  

G2023-209

[Project design]

DNDi and Mitsubishi Tanabe Pharma Co. (MTPC) aim at developing through a two-year lead optimization collaboration a novel and very promising T. cruzi active series identified from a high throughput screening of a 51,200 MTPC proprietary library and progressed to date to lead stage. The project partners plan to chemically derivatize the lead series using a well-defined and diversified medicinal chemistry strategy to improve its in vitro T. cruzi potency, maintain its favorable DMPK properties while mitigating any safety liabilities. In parallel DNDi and MTPC plan to elucidate the mechanism of action of the series notably with the expert support of University of Dundee and make use of this information to guide the lead optimization program.

*All amounts are listed at an exchange rate of USD1 = JPY151.33, the approximate exchange rate on March 31, 2024.

Appendix 2. Investment Overview (as of March 31, 2024)

Investments to date
Total investments: 33.2 billion yen (USD 219 million¹)
Total invested projects: 125 (36 active projects and 89 completed projects)

To learn more about GHIT Fund's investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

For more information, contact:
Nancy Moss, 254-729-991-028, [email protected] 
Mina Ohata at +81-36441-2032 or [email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/approximately-usd-10-8-million-invested-in-new-drug-development-for-malaria-and-ntds-in-partners-including-japanese-pharma-shionogi-mitsubishi-tanabe-and-eisai-and-europe-based-institutions-302140124.html